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Review Article
Formaldehyde-releasers in cosmetics: relationship
to formaldehyde contact allergy
Part 1. Characterization, frequency and relevance of sensitization, and
frequency of use in cosmetics
ANTON C. DE GROOT1, IAN R. WHITE2, MARI-ANN FLYVHOLM3, GERDA LENSEN1 AND PIETER-JAN COENRAADS1
1Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen,
The Netherlands, 2St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK, and 3National Research Centre
for the Working Environment, Copenhagen, Denmark
In this part of a series of review articles on formaldehyde-releasers and their relationship to formaldehyde
contact allergy, formaldehyde-releasers in cosmetics are discussed. In this first part of the article, key
data are presented including frequency of sensitization and of their use in cosmetics. In Europe, low fre-
quencies of sensitization have been observed to all releasers: 2-bromo-2-nitropropane-1,3-diol 0.4–1.2%,
diazolidinyl urea 0.5–1.4%, imidazolidinyl urea 0.3–1.4%, quaternium-15 0.6–1.9% (for DMDM hydan-
toin no recent data are available). All releasers score (far) higher prevalences in the USA; the possible
explanations for this are discussed. The relevance of positive patch test reactions has been insuffi-
ciently investigated. In the USA, approximately 20% of cosmetics and personal care products (stay-on
products: 17%, rinse-off products 27%) contain a formaldehyde-releaser. The use of quaternium-15
is decreasing. For Europe, there are no comparable recent data available. In the second part of
the article, the patch test relationship of the releasers in cosmetics to formaldehyde contact allergy
will be reviewed and it will be assessed whether products preserved with formaldehyde-releasers
may contain enough free formaldehyde to pose a threat to individuals who have contact allergy to
formaldehyde.
Key words: 2-bromo-2-nitropropane-1,3-diol; 5-bromo-5-nitro-1,3-dioxane; benzylhemiformal; cos-
metics; diazolidinyl urea; DMDM hydantoin; formaldehyde; formaldehyde-releaser; imidazolidinyl
urea; quaternium-15; sodium hydroxymethylglycinate; toiletries. © John Wiley & Sons A/S, 2010.
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Introduction
In a previous article, contact allergy to formalde-
hyde was reviewed and an inventory was made
of formaldehyde-releasers (1). An important source
of human skin contact with formaldehyde is the
use of cosmetics containing formaldehyde-releasers
as preservatives. These preservatives are added to
water-containing cosmetics (which includes per-
sonal care products/toiletries) to prevent the growth
of micro-organisms that may enter during manufac-
ture or during their usage. Microbial contamination
may cause discoloration, malodours, and physical
and chemical degradation of products, in addition
to the potential adverse events of pathogens on
consumers. Formaldehyde-releasers used in cos-
metics and permitted in the EU are shown in
Table 1 (in the USA, there is no relevant legis-
lation, either on the ingredients used in cosmet-
ics or on their permitted concentration in the final
product). The antimicrobial activity of these preser-
vatives probably results from formaldehyde release,
but it has also been postulated that at least some
of these substances act as preservatives independent
of formaldehyde release (2). In this article (first
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part), key data on these formaldehyde-releasers are
presented including synonyms, molecular formula,
chemical structure, applications (cosmetics are their
main application product group, but they are also
used in non-cosmetic products), frequency of sen-
sitization in unselected and selected patient popula-
tions and relevance of the observed positive patch
test reactions. Data on their frequency of use in cos-
metics are discussed. In the second part, their patch
test relationship to formaldehyde will be reviewed,
and it will be assessed whether products preserved
with formaldehyde-releasers may contain enough
free formaldehyde to pose a threat to individuals
who are contact allergic to formaldehyde.
Key Data on Formaldehyde-releasers Used in
Cosmetics
BENZYLHEMIFORMAL (INCI)







Permitted in cosmetics (only rinse-off products) in
the EU in a maximum concentration of 0.15%. Ben-
zylhemiformal is also used in non-cosmetic applica-
tions: biocide in metalworking fluids, slurries, filler
suspensions, adhesives, various emulsions and dis-
persions, paints and lacquers, paper industry, spin-
ning baths in the textile industry, polishes, waxes,
and cleaning products.
Frequency of sensitization
There appear to be no published reports on the
frequency of sensitization to benzylhemiformal in
a population of patients patch tested for suspected
contact dermatitis (not further selected). The expe-
rience with testing benzylhemiformal in selected
patient groups is limited in number and geographic
area; all studies having been performed by the
IVDK (Germany, Austria, Switzerland) (Table 2).
In three small series of patients with suspected
metalworking fluid dermatitis, 1–2.9% reacted to
benzylhemiformal 1% pet (3–5). In a larger series
of 947 and 1759 patients, 2.3% and 2.4% had posi-
tive patch tests (6). It was not quite clear how these
patients had been selected and there may have been
an overlap in the two populations. The relevance of
the observed positive patch test reactions was not








For cosmetic application in the EU permitted
only in rinse-off cosmetics, maximum concentration
0.1%.
5-Bromo-5-nitro-1,3-dioxane is also used in non-
cosmetic applications: biocide in cleaning/washing
agents, rinsing agents, water systems, glossing
agents, laboratory chemicals, metalworking fluids,
protein preparations, antibodies and antisera prepa-
rations, and column matrices. Also used in leather
processing and as a stabilizer and surfactant.
Frequency of sensitization
Contact allergy to 5-bromo-5-nitro-1,3-dioxane
appears to be rare or at least rarely reported. In the
period 1985–1997 in Belgium, 8521 patients were
patch tested, and only one positive reaction to 5-
bromo-5-nitro-1,3-dioxane was observed. It was not








4 DE GROOT ET AL. Contact Dermatitis 2010: 62: 2–17
Table 1. Formaldehyde releasers permitted in cosmetics in the EU with their maximum concentration
Preservative Maximum allowed concentration (%) Comments
Benzylhemiformal 0.15 Permitted in rinse-off products only
5-Bromo-5-nitro-1,3-dioxane 0.1 Permitted in rinse-off products only;
formation of nitrosamines must be avoided
2-Bromo-2-nitropropane-1,3-diol 0.1 Formation of nitrosamines must be avoided
Diazolidinyl urea 0.5
4,4-Dimethyloxazolidinea 0.1 Present in Bioban CS 1135®, a preservative in
metalworking fluids
DMDM hydantoin 0.6
5-Ethyl-1-aza-3,7-dioxabicyclo-[3.3.0] octanea 0.3 Prohibited in oral hygiene products and
products intended to come into contact with
mucous membranes. Present in Bioban CS
1246®, a preservative in metalworking
fluids.
Formaldehyde 0.2 Maximum 0.1% for products for oral hygiene
Imidazolidinyl urea 0.6
Methenamine (hexamethylenetetramine)a 0.15
Paraformaldehydea 0.2 Maximum 0.1% for products for oral hygiene
Quaternium-15 0.2
Sodium methylhydroxyglycinate 0.5
aWill be discussed later in this series of articles.
Table 2. Frequency of sensitization to benzylhemiformal in selected patients
Years of Number of Test concentration Positive (%) Current
Country study patients tested & vehicle All Women Men relevance % Mode of selection Ref.












IVDKa 1992–1995 1759 1% pet. 2.4 NS NS. Selected from 35 062
patients
(6)
IVDKa 1990–1993 947 1% pet. 2.3 NS NS. Approximately 30%
were patients working
with metals and metal
objects
(7)
IVDK, Informationsverbund Dermatologischer Kliniken, Germany, Austria, Switzerland (Information Network of Departments of
Dermatology) www.ivdk.org; NS, not stated.
aIt may be assumed that there is an overlap in the patient populations in these IVDK studies.
Applications
Permitted in cosmetics in the EU up to a
level of 0.1%. Typical use levels are 0.01–0.1%.
2-Bromo-2-nitropropane-1,3-diol is active against
fungi, yeasts, and Gram-positive and Gram-negative
bacteria, especially against Pseudomonas aerugi-
nosa. 2-Bromo-2-nitropropane-1,3-diol is also used
in non-cosmetic applications: adhesives/glues,
cleaning agents, binding agents, colouring agents,
construction materials, filling agents, flooring
agents, humidifiers, impregnating agents, metal-
working fluids, milk processing plants, paints/
lacquers, paper mills water circulating systems,
pharmaceutical products, polishes, printing inks,
slurries, surface treatment for paper, cardboard and
other non-metals, viscosity adjustors, and washing
detergents (9). 2-Bromo-2-nitropropane-1,3-diol
can degrade to formaldehyde, 2-(hydroxymethyl)-
2-nitropropane-1,3-diol (Tris nitro, a formaldehyde-
releaser used in metalworking fluids) and bromoni-
troethanol. Heat and alkaline conditions hasten this
process (10).
Frequency of sensitization
Recent experience with routine testing of 2-
bromo-2-nitropropane-1,3-diol in patients suspected
of contact dermatitis is summarized in Table 3.
Both 0.25% pet and 0.5% petrolatum 2-bromo-2-
nitropropane-1,3-diol preparations have been used
for patch testing. In the American studies, frequen-
cies of sensitization ranged from 2.1% to 3.3%
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(mean, adjusted for sample size: 2.8%) (11–16).
In the studies performed in European countries,
prevalences were consistently lower, ranging from
0.4% to 1.2% (mean, adjusted for sample size:
0.9%) (17–22). Relevance was established or con-
sidered ‘probable’ in 7–80% of the positive patients.
2-Bromo-2-nitropropane-1,3-diol has also been
tested in selected groups of patients, e.g. in patients
with suspected metalworking fluid dermatitis and
(presumably) in patients suspected of cosmetic
allergy (Table 4). This selection did not result in
higher rates of sensitization. In none of the studies
was commented on the relevance of the observed








It has been shown that diazolidinyl urea cannot
be explained by a single chemical structure (28).
The product consists of several compounds with pre-
sumably ‘compound BHU’ as dominant (30–40%):
1-(3,4-bis-hydroxymethyl-2,5-dioxo-imidazolidin-4-
yl)-1,3-bis-hydroxymethyl-urea. The remainder part
is probably many polymers of allantoin-form-
aldehyde condensation products. Only about 50%
of the theoretical amount of formaldehyde in diazo-
lidinyl urea can be released upon complete hydroly-
sis. Under basic and neutral conditions diazolidinyl
urea will degrade to only one compound, ‘compound
HU’: (4-hydroxymethyl-2,5-dioxo-imidazolidin-4-
yl)-urea, which is also present in imidazolidinyl
urea.
Applications
In cosmetics (9) permitted in the EU in a
maximum concentration of 0.5%. Typical use lev-
els are 0.1–0.3%, often combined with methyl- and
propylparaben for optimal antifungal activity.
Frequency of sensitization
Recent experience with routine testing of
diazolidinyl urea in patients suspected of contact
dermatitis is summarized in Table 5. Test concen-
trations have included 1% and 2%, both in pet.
and aq. Most studies were US multicentre stud-
ies [North American Contact Dermatitis Group
(NACDG), Mayo Clinic, three locations] and fre-
quencies of sensitization ranged from 2.4% to 3.7%
(mean, adjusted for sample size: 3.1%) (11–16,
26). In the few studies performed in European coun-
tries, prevalences were consistently lower, ranging
from 0.5% to 1.4% (mean, adjusted for sample
size: 1%, excluding pre-1990 data) (17, 18, 29,
30). Relevance was established or considered ‘prob-
able’ in 24–75% of the positive patch test reactions.
The 1% petrolatum test substance tended to detect
more cases of sensitization than the patch tests with
1% aqua.
Diazolidinyl urea has also been tested in selected
populations of patients (Table 6). This resulted in
only one small study in a higher percentage of
positive reactions (26). In none of the studies was
relevance mentioned nor was it specified how the
patients were selected.
As mentioned under ‘Chemical structure’,
diazolidinyl urea consists of numerous components.
This implies that although a number of contact aller-
gic reactions to diazolidinyl urea may be caused
by the release of formaldehyde, specific reactions
to the various other components in the biocide
are also likely to occur. A study in guinea pigs
indicated that diazolidinyl urea may be rated as
a mild sensitizer. Cross-reactions to imidazolidinyl
urea (5/8 animals) and formaldehyde (6/8 animals)
were demonstrated in animals sensitized to diazo-
lidinyl urea (31). Jordan (32) induced sensitiza-
tion to 2% diazolidinyl urea in 19 of 150 patients;
approximately 50% of these sensitized patients also
became sensitive to imidazolidinyl urea. In com-
parison, only two of another 150 were sensitized
to the same level (2%) of imidazolidinyl urea (28,
32).The presence of formaldehyde, ‘compound HU’,
and possibly other common components in both
diazolidinyl urea and imidazolidinyl urea may
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Table 3. Frequency of sensitization to 2-bromo-2-nitropropane-1,3-diol in patients suspected of contact dermatitisa
Number of Test concentration Positive (%) Current
Country Years of study patients & vehicle All Women Men relevance % Comments Ref.
UK 2004–2005 6958 0.25% pet. 1.2 1.3 1.0 NS Multicentre study (17)
USA 2001–2005 3841 0.25% pet. 2.1 51 Mayo Clinic, three locations (11)
USA 2001–2002 4897 0.5% pet. 3.3 7/63b Multicentre study, NACDG (12)
UK 2000 3063 0.5% pet. 0.8 80 Relevance (80%) = current and
past relevance in one of the
centres (674 patients)
(18)
USA 1998–2000 5800 0.5% pet. 3.1 6/58b Multicentre study, NACDG (13)
USA 1996–1998 4094 0.5% pet. 3.2 69c Multicentre study, NACDG (14)
IVDK 1992–1998 33 368 0.5% pet. 1.1 NS Multicentre study, IVDK (19)
USA 1994–1996 3074 0.5% pet. 2.3 37/32b Multicentre study, NACDG (15)
USA 1992–1994 3477 0.5% pet. 2.2 42c Multicentre study, NACDG (16)
Austria 1992–1993 11 516 0.5% pet. 0.4 0.4 0.2 NS Multicentre study (20)
Switzerland 1989–1990 2295 0.5% pet. 1.2 NS Multicentre study (21)
Europe <1990∗ 8149 0.5% pet. 0.5 45 EECDRG. 80% of the patients
came from the London area
(22)
EECDRG, European Environmental and Contact Dermatitis Research Group; IVDK, Informationsverbund Dermatologischer Kliniken,
Germany, Austria, Switzerland (Information Network of Departments of Dermatology) www.ivdk.org; NACDG, North American Contact
Dermatitis Group; NS, not stated.
aData provided back to 1990. For pre-1990 literature, see references (23, 24).
bDefinite or probable relevance (first number)/possible relevance (second number).
cPercentage includes ‘possible relevance’.
∗Exact year is unknown but it must have been before 1990.
Table 4. Frequency of sensitization to 2-bromo-2-nitropropane-1,3-diol in selected patientsa
Number of Test concentration Positive (%) Current
Country Years of study patients tested & vehicle All Women Men relevance % Mode of selection Ref.
IVDK 2004–2005 90 0.5% pet. 0 NS Patients with suspected metalworking
fluid dermatitis
(3)
IVDK 2002–2003 199 0.5% pet. 1.1 NS Patients with suspected metalworking
fluid dermatitis
(4)
Finland 2000–2002 6562 0.5% pet. 0.2 NS NS. Selected from approximately 11 800
patients
(25)
IVDK 1999–2001 148 0.5% pet. 1.4 NS Metalworkers exposed to water-based
metalworking fluids
(5)
USA 1998–2000 991 0.25% pet. 2.0 NS NS (26)
Finland 1995–1996 5150 0.5% pet. 0.5 NS NS. Selected from approximately 9400
patients
(25)
IVDKb 1992–1995 16 934 0.5% pet. 1.1 NS NS. Selected from 35 062 patients (6)
IVDKb 1990–1994 1781 0.5% pet. 1.8 NS NS. Selected from 28 349 patients (27)
IVDKb 1990–1994 11 443 0.5% pet. 1.2 NS NS. Selected from 28 349 patients (27)
IVDK, Informationsverbund Dermatologischer Kliniken, Germany, Austria, Switzerland (Information Network of Departments of
Dermatology) www.ivdk.org; NS, not stated.
aData provided back to 1990. For pre-1990 literature, see references (23, 24).
bIt may be assumed that there is an overlap in the patient populations in these IVDK studies.
Chemical structure:
Applications
Preservative mainly used in cosmetics. Permit-
ted in cosmetics in the EU at a maximum con-
centration of 0.6%. At recommended use levels,
DMDM hydantoin is active against fungi, yeast, and
Gram-positive and Gram-negative bacteria (33).
Frequency of sensitization
Recent experience with routine testing of DMDM
hydantoin in patients suspected of contact dermati-
tis is summarized in Table 7. Test concentrations
have included 1% in pet. and aq. and earlier 3% aq.
Most studies were US multicentre studies (NACDG,
Mayo Clinic, three locations) (11–16, 26). Fre-
quencies of sensitization have ranged from 0.5% to
3.4% but were usually in the 1.3–2.5% range (mean,
adjusted for sample size: 2%). The petrolatum-based
test substances usually scored slightly higher than
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the aqueous preparations. Relevance was established
or considered ‘probable’ in 15–86% of the positive
patch test reactions. In Europe, only old data are
available.
In several studies, selected patients (not stated
how they were selected) have been tested with
DMDM hydantoin 2% aq. and/or 2% pet. (Table 8).
Neither the selection process nor the use of higher
test concentrations resulted in an increase in fre-
quencies of detection of sensitization. In an IVDK
study, relevance was found in 31% of the positive
patch test reactions. Causative products were mainly
cosmetics (30%) and topical drugs (22%); the other
products were not mentioned (36).
IMIDAZOLIDINYL UREA (INCI)
CAS 39236-46-9
Synonyms: Imidurea (INN); bis(methylolhy-




Table 5. Frequency of sensitization to diazolidinyl urea in patients suspected of contact dermatitisa
Number of Test concentration Positive (%) Current
Country Years of study patients & vehicle All Women Men relevance % Comments/setting Ref.
UK 2005 6958 2% pet. 1.1 1.2 0.9 NS Multicentre study (17)
USA 2001–2005 3842 1% pet. 3.5 75 Mayo Clinic, three locations (11)
USA 2001–2005 3840 1% aq. 2.4 75 Mayo Clinic, three locations (11)
USA 2001–2002 4897 1% pet. 3.1 31/63b Multicentre study, NACDG (12)
USA 2001–2002 4897 1% aq. 3.2 33/58b Multicentre study, NACDG (12)
Sweden 2000 3790 1% pet. 1.4 NS Multicentre study (29)
USA 1998–2000 1033 1% pet. 2.9 NS Mayo Clinic, three locations (26)
USA 1998–2000 1319 1% aq. 2.5 NS Mayo Clinic, three locations (26)
UK 2000 3062 2% pet. 0.7 90 Relevance (90%) = present
and past relevance in one
centre (674 patients)
(18)
USA 1998–2000 5802 1% pet. 3.0 24/64b Multicentre study, NACDG (13)
USA 1998–2000 5778 1% aq. 2.6 28/55b Multicentre study, NACDG (13)
USA 1996–1998 4096 1% pet. 3.7 92c Multicentre study, NACDG (14)
USA 1996–1998 4094 1% aq. 2.9 85c Multicentre study, NACDG (14)
USA 1994–1996 3085 1% pet. 3.7 48/39b Multicentre study, NACDG (15)
USA 1994–1996 3060 1% aq. 3.7 44/41b Multicentre study, NACDG (15)
USA 1992–1994 3481 1% pet. 3.0 65c Multicentre study, NACDG (16)
USA 1992–1994 3471 1% aq. 3.1 65c Multicentre study, NACDG (16)
The Netherlands 1984–1988 2400 2% aq. 0.5 NS One centre, Nijmegen (30)
NACDG, North American Contact Dermatitis Group; NS, not stated.
aData provided back to 1990. For pre-1990 literature, see references (23, 24).
bDefinite or probable relevance (first number)/possible relevance (second number).
cPercentage includes ‘possible relevance’.
Table 6. Frequency of sensitization to diazolidinyl urea in selected patientsa
Number of Test concentration Positive (%) Current
Country Years of study patients tested & vehicle All Women Men relevance % Mode of selection Ref.




USA 1998–2000 285 2% pet. 4.9 NS NS (26)
Finland 1995–1996 2911 1% pet. 1.2 NS NS. Selected from
approx. 9400 patients
(25)
IVDKb 1992–1995 14 881 NS 1.0 NS NS. Selected from
35 062 patients
(6)
IVDKb 1990–1994 7812 2% pet. 1.3 NS NS. Selected from
28 349 patients
(27)
IVDK, Informationsverbund Dermatologischer Kliniken, Germany, Austria, Switzerland (Information Network of Departments of
Dermatology) www.ivdk.org; NS, not stated.
aData provided back to 1990. For pre-1990 literature, see references (23, 24).
bIt may be assumed that there is an overlap in the patient populations in these IVDK studies.
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Table 7. Frequency of sensitization to DMDM hydantoin in patients suspected of contact dermatitisa
Number of Test concentration Positive (%) Current
Country Years of study patients & vehicle All Women Men relevance % Comments Ref.
USA 2001–2005 3757 1% pet. 2.2 75 Mayo Clinic, three locations (11)
USA 2001–2005 3428 1% aq. 1.3 86 Mayo Clinic, three locations (11)
USA 2001–2002 4897 1% pet. 2.8 29/64b Multicentre study, NACDG (12)
USA 2001–2002 4897 1% aq. 2.2 34/57b Multicentre study, NACDG (12)
USA 1998–2000 1321 1% pet. 0.8 NS Mayo Clinic, three locations (26)
USA 1998–2000 1042 1% aq. 0.5 NS Mayo Clinic, three locations (26)
USA 1998–2000 5801 1% pet. 2.0 15/75b Multicentre study, NACDG (13)
USA 1998–2000 5767 1% aq. 1.6 20/60b Multicentre study, NACDG (13)
USA 1994–1999 474 NS 3.4 NS One centre study, Kansas City (34)
USA 1996–1998 4093 1% pet. 2.6 93c Multicentre study, NACDG (14)
USA 1996–1998 4093 1% aq. 1.9 82c Multicentre study, NACDG (14)
USA 1994–1996 3082 1% pet. 2.3 49/39b Multicentre study, NACDG (15)
USA 1994–1996 3064 1% aq. 2.1 44/39b Multicentre study, NACDG (15)
USA 1992–1994 3485 1% pet. 1.6 56c Multicentre study, NACDG (16)
USA 1992–1994 3479 1% aq. 1.8 56c Multicentre study, NACDG (16)
Switzerland 1989–1990 2295 3% aq. 1.7 NS Multicentre study (21)
The Netherlands 1985 501 3% aq. 1.2 NS Multicentre study (35)
NACDG, North American Contact Dermatitis Group; NS, not stated.
aData provided back to 1990. For pre-1990 literature, see references (23, 24).
bDefinite or probable relevance (first number)/possible relevance (second number).
cPercentage includes ‘possible relevance’.
Table 8. Frequency of sensitization to DMDM hydantoin in selected patientsa
Number of Test concentration Positive (%) Current
Country Years of study patients tested & vehicle All Women Men relevance % Mode of selection Ref.
USA 2001–2005 411 2% aq. 1.2 60 NS (11)












IVDK, Informationsverbund Dermatologischer Kliniken, Germany, Austria, Switzerland (Information Network of Departments of
Dermatology) www.ivdk.org; NS, not stated.
aData provided back to 1990. For pre-1990 literature, see references (23, 24).
bRelevance of the two study protocols together.
It has been shown that imidazolidinyl urea
cannot be explained by a single chemical struc-
ture (28). The product consists of ‘compound
HU’: (4-hydroxymethyl-2,5-dioxo-imidazolidin-4-
yl)-urea (10%), allantoin (20%), two unidenti-
fied presumably formaldehyde releasing compounds
(10%) and 60% (most likely) numerous polymers of
allantoin-formaldehyde condensation products. Only
about 75% of the theoretical amount of formalde-
hyde in imidazolidinyl urea (2 moles of formalde-
hyde per mole imidazolidinyl urea) can be released
upon complete hydrolysis (37). ‘Compound HU’
is also present in diazolidinyl urea degraded under
basic and neutral conditions.
Applications
In cosmetics (9) permitted in the EU in a maxi-
mum concentration of 0.6%. The typical use level is
0.3%, often in combination with methyl- and propy-
lparaben for optimal antifungal activity.
Frequency of sensitization
Recent experience with routine testing of
imidazolidinyl urea in patients suspected of contact
dermatitis is summarized in Table 9. Test concentra-
tions have included 2% in pet. and aq. Most stud-
ies were US multicentre studies (NACDG, Mayo
Clinic, three locations) (11–16, 26, 38) and fre-
quencies of sensitization ranged from 1.3% to 3.3%.
The petrolatum-based test substances nearly always
scored higher than the aqueous ones (mean for the
petrolatum-based preparation, adjusted for sample
size: 2.7%). Frequencies of sensitization in Europe
were consistently lower and ranged from 0.3 to 1.4%
(mean, adjusted for sample size: 0.7%) (17, 18, 20,
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21, 25, 29). Relevance was established or consid-
ered ‘probable’ in 21–90% of the positive patch
test reactions.
In several studies, selected patients have been
tested with imidazolidinyl urea 2% pet. (Table 10).
This did not result in higher prevalences of
sensitization, not even in a group suspected of cos-
metic dermatitis (25).
As mentioned under ‘Chemical structure’, imi-
dazolidinyl urea consists of numerous components.
This implies that although a number of contact aller-
gic reactions to imidazolidinyl urea may be caused
by the release of formaldehyde, specific reactions to
the various other components in the biocide are also
likely to occur (28). The presence of formaldehyde,
‘compound HU’ and possibly other common com-
ponents in both imidazolidinyl urea and diazolidinyl
urea may explain why many patients in the patch test
react to both preservatives.
QUATERNIUM-15 (INCI)
CAS 4080-31-3







Permitted in cosmetics in the EU in a maximum
concentration of 0.2% with typical use levels of
0.05–0.2%, quaternium-15 is a highly active, broad-
spectrum preservative providing effective antimicro-
bial activity against bacteria (particularly effective
against Pseudomonas species), yeast, and molds.
It has been frequently used in cosmetics (9).
Quaternium-15 may also be present in non-cosmetic
applications including metalworking fluids, deter-
gents and soaps, floor waxes and polishes, inks,
latex-based paints, laundry starch, paper and pulp
products, textile finishing solutions, spinning emul-
sions, printing pastes, joint cements (40), and pho-
tocopier toner.
Frequency of sensitization
Quaternium-15 pet is included in most baseline
patch testing series including that in Europe. Recent
experience with routine testing is summarized in
Table 11. Test concentrations have included 1%
and 2% in pet. As with formaldehyde (1), there
are major differences in the frequencies of sen-
sitization between USA and European studies. In
the multicentre studies from the USA frequencies
of sensitization have ranged from 7.1% to 9.6%
(mean, adjusted for sample size: 8.8%) (11–16,
39). In the European studies, prevalences were con-
sistently lower, ranging from 0.6% to 1.9% (mean,
adjusted for sample size: 1.1%) (17, 18, 20, 21,
25, 29, 41–45). In other non-European countries
such as Israel and Turkey, equally low rates were
observed (46–48). Relevance was established or
considered ‘probable’ in 29–90% of the positive
patch test reactions. In the USA, the 2% pet. test
substance detected more cases of sensitization than
the 1% patch test material, but direct comparisons
in the same populations are lacking and the 1%
preparation was used in one study only (39). Of
the positive patch test reactions to quaternium-15 in
89 patients, 60 (67%) were considered relevant. The
most frequently incriminated products were mois-
turizers (n = 46), hair preparations (non-colouring,
n = 19), and makeup (n = 4). There were three
cases of occupational contact dermatitis, caused by
hair products and a barrier cream (49).
The IVDK has tested selected patients with
quaternium-15, but it was not stated how they were
selected; this did not result in higher frequencies of
detection of sensitization (Table 12).
SODIUM HYDROXYMETHYLGLYCINATE (INCI)
CAS 70161-44-3
Synonyms: glycine, N-(hydroxymethyl)-, sodium
salt (1:1); hydroxymethylaminoacetic acid, sodium





Preservative in cosmetics (maximum permitted in
the EU: 0.5%). Non-cosmetic applications include
as neutralizing agent for acids/acrylics polymers, in
cleaning/washing agents, and in rinsing agents.
Frequency of sensitization
There appear to be no documented cases of
sensitization to sodium hydroxymethylglycinate.
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Table 9. Frequency of sensitization to imidazolidinyl urea in patients suspected of contact dermatitisa
Number of Test concentration Positive (%) Current
Country Years of study patients & vehicle All Women Men relevance % Comments Ref.
UK 2004–2005 6958 2% pet. 0.9 1.0 0.7 NS Multicentre study (17)
USA 2001–2005 3819 2% pet. 2.8 74 Mayo Clinic, three locations (11)
USA 2001–2005 3843 2% aq. 2.1 76 Mayo Clinic, three locations (11)
USA 2001–2002 4897 2% pet. 3.0 26/66b Multicentre study, NACDG (12)
USA 2001–2002 4909 2% aq. 1.8 30/61b Multicentre study, NACDG (12)
USA 2002–2004 5784 2% aq. 1.3 NS Multicentre study, NACDG (38)
USA 2002–2004 5784 2% pet. 2.5 NS Multicentre study, NACDG.
The test preparation was
found to contain 3.1%
imidazolidinyl urea
(38)
Finland 2000–2002 11 794 2% pet. 0.8 NS Multicentre study (25)
USA 1998–2000 1321 2% pet. 3.3 NS Mayo Clinic, three locations (26)
USA 1998–2000 1322 2% aq. 1.7 NS Mayo Clinic, three locations (26)
USA 1998–2000 5821 2% pet. 2.0 27/52b Multicentre study, NACDG (13)
USA 1998–2000 5784 2% aq. 2.5 21/69b Multicentre study, NACDG (13)
UK 2000 3063 2% pet. 0.5 90 Relevance (90%) = current
and past relevance in one
centre (674 patients) only
(18)
Sweden 2000 3790 2% pet. 1.4 NS Multicentre study (29)
USA 1996–1998 4094 2% pet. 3.2 92c Multicentre study, NACDG (14)
USA 1996–1998 4101 2% aq. 2.5 86c Multicentre study, NACDG (14)
USA 1988–1997 927 2% pet. 1.9 NS One centre, Boston (39)
USA 1994–1996 3080 2% pet. 3.1 45/43b Multicentre study, NACDG (15)
USA 1994–1996 3101 2% aq. 2.6 47/34b Multicentre study, NACDG (15)
USA 1992–1994 3482 2% pet. 2.6 58c Multicentre study, NACDG (16)
USA 1992–1994 3523 2% aq. 1.9 54c Multicentre study, NACDG (16)
Austria 1992–1993 11 516 2% pet. 0.3 0.3 0.3 NS Multicentre study (20)
Switzerland 1989–1990 2295 2% pet. 1.0 NS Multicentre study (21)
NACDG, North American Contact Dermatitis Group; NS, not stated.
aData provided back to 1990. For pre-1990 literature, see references (23, 24).
bDefinite or probable relevance (first number)/possible relevance (second number).
cPercentage includes ‘possible relevance’.
Table 10. Frequency of sensitization to imidazolidinyl urea in selected patientsa
Number of Test concentration Positive (%) Current
Country Years of study patients tested & vehicle All Women Men relevance % Mode of selection Ref.




IVDKb 1992–1995 17 327 2% pet. 0.6 NS NS. Selected from
35 062 patients
(6)
IVDKb 1990–1994 11 452 2% pet. 0.6 NS NS. Selected from
28 349 patients
(27)
IVDK, Informationsverbund Dermatologischer Kliniken, Germany, Austria, Switzerland (Information Network of Departments of
Dermatology) www.ivdk.org; NS, not stated.
aData provided back to 1990. For pre-1990 literature, see references (23, 24).
bIt may be assumed that there is an overlap in the patient populations in these IVDK studies.
Frequency of Use of Formaldehyde-releasers in
Cosmetics and Toiletries
USA
In the USA, imidazolidinyl urea was present in
13%, DMDM hydantoin in 5%, quaternium-15 in
3.7%, diazolidinyl urea in 3.6% and formalde-
hyde per se as a preservative in <1% of approx-
imately 20 000 cosmetic formulae voluntarily reg-
istered by cosmetic companies in the FDA Vol-
untary Cosmetic Registration Database in 1996.
Imidazolidinyl urea ranked 3rd in the top-10 of most
frequently used cosmetic preservatives after methyl-
and propylparaben, DMDM 7th, quaternium-15 9th,
and diazolidinyl urea 10th (50). In 2003, the most
frequently used formaldehyde donor was –again
–imidazolidinyl urea (present in 2038 products),
followed by DMDM hydantoin (993 products),
diazolidinyl urea (725 products), quaternium-15
(516 products), and 2-bromo-2-nitropropane-1,3-
diol (168 products). Formaldehyde per se as a
preservative was present in only 118 products. It
was not stated what the total number of at the FDA
registered cosmetic products was in 2003 (51).
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The most recent data from the FDA Volun-
tary Cosmetic Registration Program Database are
shown in Table 13 (1) (Anton de Groot 2009,
data obtained from FDA). Approximately one in
every five cosmetics will contain a formaldehyde-
releaser; for the stay-on cosmetics, this is one in
six, and in rinse-off products (where they are less
likely to cause harm) one in four. The most fre-
quent releaser is still imidazolidinyl urea (7%), fol-
lowed by DMDM hydantoin (5.4%), diazolidinyl
urea (4.5%), and quaternium-15 (1.4%). 5-Bromo-5-
nitro-1,3-dioxane, 2-bromo-2-nitropropane-1,3-diol,
formaldehyde per se, and (the more recently intro-
duced) sodium methylhydroxyglycinate are present
in <1% of all products; benzylhemiformal is not
used at all.
Another US database, the SKIN DEEP cosmetic
safety database collected and published by the
Environmental Working Group (www.cosmeticsdata
base.com), has the ingredients of 41 113 cos-
metics and personal care products on file (2091
brands, 1338 companies, 8295 ingredients). As
in the FDA data, benzylhemiformal is not used
at all, and 5-bromo-5-nitro-1,3-dioxane (0.03%),
2-bromo-2-nitropropane-1,3-diol (0.3%), formalde-
hyde (0.1%), and sodium methylhydroxyglycinate
(0.5%) are present in <1% of the products. In
this database, which was filled from 2004 on,
diazolidinyl urea was the most frequently present
Table 11. Frequency of sensitization to quaternium-15 in patients suspected of contact dermatitisa
Number of Test concentration Positive (%) Current
Country Years of study patients & vehicle All Women Men relevance % Comments/setting Ref.
Denmark 1985–2005 14 993 1% pet. 0.9 1.1 0.5 NS One centre, Copenhagen (41)
United Kingdom 2004–2005 6958 1% pet. 1.9 2.2 1.1 NS Multicentre study (17)
USA 2001–2005 3841 1% pet. 8.1 76 Mayo Clinic, three locations (11)
Israel 1998–2004 2156 1% pet. 0.8 NS One centre, Tel Aviv (46)
Turkey 1992–2004 1038 1% pet. 0.8 1.2 0 NS One centre, Ankara (47)
Europe 2004 7454 1% pet. 1.4 NS 31 departments, 11 countries,
ESSCA
(42)
Europe 2002–2003 5845 1% pet. 1.2 NS 17 centres in nine countries,
ESSCA
(43)
USA 2001–2002 4910 2% pet. 8.4 29/56b Multicentre study, NACDG (12)
Finland 2000–2002 11 802 1% pet. 0.8 NS Multicentre study (25)
Czech Republic 1997–2001 7642 1% pet. 0.7 0.8 0.5 NS Multicentre study (44)
United Kingdom 2000 3063 1% pet. 1.3 90 Relevance (90%) = current
and past relevance in one
centre (674 patients) only-
(18)
Sweden 2000 3790 1% pet. 1.2 NS Multicentre study (29)
Europe 1996–2000 26 210 1% pet. 1.3 1.5 1.0 NS 10 centres, seven countries,
EECDRG
(45)
Israel 1999–2000 943 1% pet. 0.6 0.7 0.5 NS One centre, Petah Tiqwa (48)
USA 1998–2000 5832 2% pet. 9.2 35/52b Multicentre study, NACDG (13)
USA 1996–1998 3436 2% pet. 9.0 89c Multicentre study, NACDG (14)
USA 1988–1997 927 1% pet. 7.1 NS One centre, Boston (39)
USA 1994–1996 3110 2% pet. 9.2 58/27b Multicentre study, NACDG (15)
Finland 1995–1996 9364 1% pet. 1.1 NS Multicentre study (25)
USA 1992–1994 3500 2% pet. 9.6 78c Multicentre study, NACDG (16)
Austria 1992–1993 11 516 1% pet. 0.6 0.7 0.5 NS Multicentre study (20)
Switzerland 1989–1990 2295 1% pet. 1.0 NS Multicentre study (21)
EECDRG, European Environmental and Contact Dermatitis Research Group; ESSCA, European Surveillance System on Contact Allergies
www.essca-dc.org; NACDG, North American Contact Dermatitis Group; NS, not stated.
aData provided back to 1990. For pre-1990 literature, see references (23, 24).
bDefinite or probable relevance (first number)/possible relevance (second number).
cPercentage includes ‘possible relevance’.
Table 12. Frequency of sensitization to quaternium-15 in selected patients
Number of Test concentrations Positive (%) Current
Country Years of study patients tested & vehicle. All Women Men relevance % Mode of selection Ref.
IVDKa 1992–1995 18 977 1% pet. 0.5 NS NS. Selected from 35 062
patients
(6)
IVDKa 1990–1994 11 017 1% pet. 0.6 NS NS. Selected from 28 349
patients
(27)
IVDK, Informationsverbund Dermatologischer Kliniken, Germany, Austria, Switzerland (Information Network of Departments of
Dermatology) www.ivdk.org; NS, not stated.
aIt may be assumed that there is an overlap in the patient populations in these IVDK studies.
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Table 13. Frequency of use of formaldehyde and releasers in 33 212 cosmetics and toiletries in the USA: FDA Voluntary Cosmetic
Registration Database, 15 September 2008
Total number of products Stay-on cosmetic Rinse-off product
containing the preservative (% of 25 077 (% of 835
Preservative (% of total: n = 33 212) stay-on cosmetics) rinse-off products)
Benzylhemiformal 0
5-Bromo-5-nitro-1,3-dioxane 26 (0.1%) 6 (0.02%) 20 (0.2%)
2-Bromo-2-nitropropane-1,3-diol 174 (0.5%) 144 (0.6%) 30 (0.4%)
Diazolidinyl urea 1496 (4.5%) 1064 (4.2%) 432 (5.3%)
DMDM hydantoin 1780 (5.4%) 754 (3.0%) 1026 (12.6%)
Formaldehyde (solution) 99 (0.3%) 42 (0.2%) 57 (0.7%)
Imidazolidinyl urea 2333 (7.0%) 1951 (7.8%) 382 (4.7%)
Quaternium-15 473 (1.4%) 249 (1.0%) 224 (2.8%)
Sodium hydroxymethylglycinate 82 (0.2%) 31 (0.1%) 51 (0.6%)
Total 6463 (19.5%) 4241 (16.9%) 2222 (27.3%)
formaldehyde-releaser (7.8%), followed by DMDM
hydantoin (6.6%) and imidazolidinyl urea (3.9%).
They are both used in stay-on and in rinse-off
products. Quaternium-15 is present in 1.4% of the
products, but in none of the 6614 moisturizers.
Europe
There is no European counterpart of the FDA pro-
gramme and all our efforts to obtain information
from the European Cosmetics Industry Associa-
tion (COLIPA) have remained fruitless or even
unanswered. Data on usage of formaldehyde and
releasers in cosmetics sold in Europe, therefore,
are scant and some possibly outdated. In 1992,
161 rinse-off products and 124 leave-on products
produced in various European countries and the
USA were investigated in Denmark for the pres-
ence of formaldehyde. Of them, 30% proved to
contain (free and bound) formaldehyde. In eight
products, free formaldehyde exceeded 500 p.p.m.,
but 7/8 were rinse-off products (52). In the same
year, in Switzerland 34 cosmetic products were
investigated for the presence of formaldehyde using
three analytical methods including HPLC. Nine-
teen products (56%) were found to contain free
formaldehyde (53). In 1998, 100 moisturizers sold
in Sweden were analysed for the presence and
amount of preservatives. Thirty-five products con-
tained a formaldehyde-releaser: 23 imidazolidinyl
urea, three diazolidinyl urea, three DMDM hydan-
toin, two 2-bromo-2-nitropropane-1,3-diol, and one
quaternium-15. Ten products contained more than
200 p.p.m. formaldehyde (one product >500 p.p.m.),
in nine of these a formaldehyde-releaser was present
(four imidazolidinyl urea, four diazolidinyl urea, one
quaternium-15). The concentrations of the releasers
did not exceed the EEC permitted maximum in any
case (54).
In 2000, Rastogi in Denmark analysed preser-
vatives in 67 skin creams to verify the data on
the product labels. Five (7%) contained 2-bromo-
2-nitropropane-1,3-diol, none 5-bromo-5-nitro-1,3-
dioxane, and 34 (51%) contained formaldehyde,
either from formaldehyde-releasers or from its pres-
ence per se (55). In 2005, data on the use of
preservatives in various product categories were
obtained for products registered in the Danish Prod-
uct Register Database (PROBAS). The database has
information on the ingredients of 1170 cosmetics
and toiletries. 2-Bromo-2-nitropropane-1,3-diol was
present in 36 products (3.1%), quaternium-15 in
13 (1.1%), diazolidinyl urea in 6 (0.5%), formalde-
hyde in 17 (1.5%), and imidazolidinyl urea in 184
(15.7%). DMDM hydantoin or other releasers were




do not appear to be important sensitizers. It should
be appreciated, however, that these chemicals are
not routinely tested and sensitization, therefore, may
go undetected. For 5-bromo-5-nitro-1,3-dioxane, at
this point it is unclear whether the chemical is actu-
ally–as suggested in literature –a formaldehyde-
releaser. Quaternium-15 is the only formaldehyde-
releaser that is included in the baseline series in
the USA and in Europe and thus routinely tested
in patients suspected of contact dermatitis. The
major differences in the frequencies of sensitization
to this preservative in the USA (7.1–9.6%; mean,
adjusted for sample size: 8.8) and European stud-
ies (0.6–1.9%; mean, adjusted for sample size: 1.1)
(Table 11) are remarkable. As Table 14 shows, this
is also the case for the other releasers for which
adequate data are available. On the lower end of the
frequency range, the scores are five times higher
in the USA, the means (adjusted for sample size)
approximately three to four times and at the higher
end, the scores are some 2.5 times higher in the
USA than in Europe. What could be the cause of
these differences?
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Table 14. Frequency of sensitization of formaldehyde-releasers in the USA and Europe
Chemical Frequency of sensitization
USA (mean, adjusted for sample size) Europe (mean, adjusted for sample size) References
2-Bromo-2-nitropropane-1,3-diol 2.1–3.3% (2.8) 0.4–1.2% (0.9%) Table 3
Diazolidinyl urea 2.4–3.7% (3.1) 0.5–1.4% (1.0%) Table 5
DMDM hydantoin 0.5–3.4% (2.0) No adequate data Table 7
Imidazolidinyl urea 1.3–3.3% (2.7) 0.3–1.4% (0.7%) Table 8
Quaternium-15 7.1–9.6% (8.8) 0.6–1.9% (1.1%) Table 10
Table 15. Parameters that may influence frequencies of
sensitization
Technical
Patch test systems (materials, e.g. Finn Chambers®)
Suppliers, test concentrations, test vehicles for allergens
Exposure time to the test allergen (1D or 2D)
Reading and interpretation of the reaction. Interpretation of
weak positive reactions, recognition of irritant reactions
Mode of ascertaining relevance
Sometimes read after 2D only
Sometimes angry back syndrome not taken into account
In older publications probably more often irritant reactions
Technical problems with patch test materials: wrong
concentrations (38, 56, 57)
Epidemiological
Referral pattern (secondary or tertiary centre, special interests)
Population characteristics: sex, age, occupation, etc.
(MOHLFA)
Mode of selection for testing with the standard series
Mode of selection for testing with other series
Exposure of the population to allergens (regional, national,
international), including local prescribing habits (e.g.
Eucerin with bronopol) (10)
Miscellaneous
Different periods of investigation (in which trends may have
changed)
Natural variations in reactions (test not absolutely reliable,
discordant results with double or successive testing)
Multicentre or monocentre study
Many parameters influence the frequencies of
sensitization in patch test studies (Table 15). As a
consequence, there are many possible explanations
for the differences between the USA and Europe,
including a different test protocol in the USA or
larger exposure of the US population to the releasers
in cosmetics and other sources. The technical part
of the US test protocol does not differ substantially
from that in Europe with one exception: quaternium-
15 was usually tested at 2% in pet in the USA
versus 1% in Europe (comparative studies are not
available). However, the NACDG and the Mayo
Clinic, from which most USA data originate, are
tertiary referral centres, and thus it may be assumed
that their population has undergone stricter selec-
tion, resulting in an increased likelihood of finding
contact allergies therein. To study this possibility,
we have compared the reported frequencies of sen-
sitization to the 20 allergens that are routinely tested
in both the USA and in Europe (de Groot AC, Coen-
raads PJ, Maibach HI, unpublished data). In 17 of
the 20 allergens, frequencies of sensitization were
higher in the USA. The highest scores were for
quaternium-15 (mean 7.1 times more frequent in
the USA), neomycin (4.1), and formaldehyde (4.0).
The high frequency of neomycin can readily be
explained: this topical antibiotic is –contrary to the
situation in Europe –widely used there (also by doc-
tors) and can be obtained over-the-counter. In the
USA, the mean frequency of sensitization of all 20
allergens together is about two times higher than in
Europe. If we leave formaldehyde and quaternium-
15 out (as we investigate these) and also neomycin
(because we have a plausible explanation for its
higher frequency), the mean frequency of sensitiza-
tion to the other 17 allergens as a group is 1.4 times
higher in the USA. Thus, we tentatively assume
that frequencies of sensitization in the USA are on
average 1.4 times higher than in Europe attributable
to protocol differences including interpretation and
selection of patients to be patch tested. This only
partly explains the differences in sensitization fre-
quency to 2-bromo-2-nitropropane-1,3-diol, diazo-
lidinyl urea, imidazolidinyl urea, and quaternium-15
between the USA and Europe. The second possi-
ble explanation would be a higher exposure of the
US population to formaldehyde-releasers. None of
them are known important occupational sensitizers,
and therefore the most important exposure should
come from cosmetics, notably the stay-on products.
The FDA data (Table 13) show that 2-bromo-2-
nitropropane-1,3-diol and quaternium-15 are present
in not more than 1% of the stay-on products on file.
Although no such data are available for Europe, it
seems very unlikely that the presence of quaternium-
15 in 1% of all stay-on products (and in the SKIN
DEEP cosmetic safety database collected and pub-
lished by the Environmental Working Group in none
of 6614 moisturizers) could result in a 7–9% fre-
quency of sensitization in the USA in patients sus-
pected of contact dermatitis. More leave-on products
contain diazolidinyl urea (4.2%), DMDM hydan-
toin (3%), or imidazolidinyl urea (7.8%), but –again
–comparison with Europe cannot be made because
of lack of European data. In addition, we know noth-
ing about the concentrations of the formaldehyde-
releasers used in the USA. Although there are strict
limitations in Europe (Table 1), there are no such
limits to the concentrations in the USA. In addi-
tion, people in the USA might be heavier users of
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cosmetics than individuals in the European popu-
lation. A third possible explanation for the higher
frequencies in the USA may be found in the relation
between formaldehyde-releasers and formaldehyde
contact allergy. In Table 16 (which will be dis-
cussed in detail in part 2 ), it is shown what per-
centage of patients allergic to formaldehyde did
also react to the various formaldehyde-releasers in
relevant studies. Adjusted for sample size, the per-
centage is 6% for 2-bromo-2-nitropropane-1,3-diol,
21% for diazolidinyl urea, 19% for DMDM hydan-
toin, 14% for imidazolidinyl urea, and 40% for
quaternium-15. The mean frequencies of sensiti-
zation to formaldehyde, adjusted for sample size,
are 8.7% in the USA and 2.2% in Europe [cal-
culated from Table 5 in part I of this study (1)].
After correction for stricter selection (1:1.4 = 0.71),
the mean frequency of formaldehyde sensitization
in the USA is 0.71 × 8.7% = 6.2%. The difference
with Europe then is 6.2–2.2% = 4%. As 6% of
patients allergic react to 2-bromo-2-nitropropane-
1,3-diol, 6% of this 4% = 0.24% of the frequency
of sensitization to 2-bromo-2-nitropropane-1,3-diol
can be attributed to the higher frequency of sen-
sitization to formaldehyde in the USA (Table 17).
For diazolidinyl urea, this is 21% × 4% (0.84%),
for DMDM hydantoin 19% × 4% (0.76%), for
imidazolidinyl urea 14% × 4% (0.56%), and for
quaternium-15, which reacts in 40% of patients
allergic to formaldehyde, 40% × 4%= 1.6%. After
these adjustments, the differences between the USA
and Europe are far smaller for all releasers except
one (Table 17). Quaternium-15 in the USA would
still yield 4.65% positive reactions under European
conditions (i.e. after correction for selection and the
higher frequency of formaldehyde allergy) versus
1.1% in Europe. Whether this is due to more fre-
quent use in cosmetics or in other products is caused
by higher concentrations in such products or can be
explained by the generally higher patch test con-
centration in the USA (2% versus 1% in Europe)
is unknown. We suggest that prospective studies be
initiated where the routine series is supplemented
with quaternium-15 2% in pet. In addition, the
US cosmetics industry should be approached for
information on use concentrations of quaternium-15
and the presence of quaternium-15 in non-cosmetic
products should be investigated.
An interesting finding has been that for dia-
zolidinyl urea, DMDM hydantoin, and imidazo-
lidinyl urea, test substances in petrolatum yielded
more positive reactions than the test allergens in
aqueous solutions. This is unexpected, at least for
cases caused by formaldehyde sensitivity. It may be
assumed –as formaldehyde is released by hydrol-
ysis, for which water is needed –that the amount
of free formaldehyde in patch test substances with
petrolatum as vehicle is very low or it is even absent.
However, perspiration water under the test materials
will probably release formaldehyde from the petro-
latum test substance and also in the skin itself the
substance may be metabolized leading to formalde-
hyde release (6).
Table 16. Percentages positive to formaldehyde-releasers in patients allergic to formaldehydea
Number of Percentage of patients allergic to formaldehyde with positive reactions to:
Country and patients allergic 2-Bromo-2- Diazolidinyl DMDM Imidazolidinyl Quaternium-15
period of study to formaldehyde nitropropane-1,3-diol urea hydantoin urea Ref.
UK 2004–2005 142 10 30 23 52 (58)
USA 1992–2004 2225 24.5 19 17 (56)
UK 1982–1993 629 4 4 6 47 (59)
Austria 1992–1993 105 1 4 18 (20)
USA 1982–1989 454 10 10 31 (24)
USA <1980 30 30 (60)
Data on <20 patients are presented in references (10, 61).
aOnly studies with at least 20 positive reactions to formaldehyde are included.
Table 17. Comparison between frequency of sensitization to formaldehyde-releasers in USA and Europe after adjusting for selection
and higher frequency of sensitization to formaldehyde in the USA
Mean frequency Correction for Mean frequency
of sensitization After correction higher prevalence of of sensitization
in the USA (%) for selection formaldehyde allergy After correction in Europe (%)
2-Bromo-2-nitro-
propane-1,3-diol 2.8 0.71 × 2.8 = 1.99 6% × 4% = 0.24% 1.99 − 0.24 = 1.75% 0.9
Diazolidinyl urea 3.1 0.71 × 3.1 = 2.20 21% × 4% = 0.84% 2.20 − 0.84 = 1.36% 1.0
DMDM hydantoin 2.0 0.71 × 2.0 = 1.42 19% × 4% = 0.76% 1.42 − 0.76 = 0.66% No data available
Imidazolidinyl urea 2.7 0.71 × 2.7 = 1.92 14% × 4% = 0.56% 1.92 − 0.56 = 1.36% 0.7
Quaternium-15 8.8 0.71 × 8.8 = 6.25 40% × 4% = 1.6% 6.25 − 1.6 = 4.65% 1.1
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Relevance
Determining the relevance of positive patch test
reactions is considered one of the most difficult, if
not the most difficult, aspect of patch testing (62).
This is illustrated by the fact that of the 33 stud-
ies cited, only eight (24%) have provided data on
relevance. Five of these eight were the continu-
ing 2-year period studies of the NACDG (12–16).
These investigators divide present relevance into
‘definite’, ‘probable’, and ‘possible’. Possible rel-
evance is considered if the patient was exposed to
circumstances in which skin contact with materials
known to contain the putative allergen would likely
occur and the rash distribution and clinical sit-
uation fit. This may result, as indicated by the
NACDG itself, in an overestimation of present rel-
evance (13). It should also be noted that the highly
selected patient population that the NACDG patch
tests is often sent back to the referring dermatol-
ogists for follow-up. This could –again according
to the NACDG –result in an overestimation of the
true possible relevance of a particular test aller-
gen. In the eight studies with relevance figures,
very different data on relevance considered ‘estab-
lished’ or ‘probable’ have been reported: 2-bromo-
2-nitropropane-1,3-diol 7–80%, diazolidinyl urea
24–75%, DMDM hydantoin 15–86%, imidazo-
lidinyl urea 21–90%, and quaternium-15 29–90%.
Unfortunately, in not one of these papers was
it stated what the causative products containing
the allergens were (with the exception of refer-
ence (22), they were not designed for provid-
ing this information). There is an urgent need for
more detailed description of relevance assessments
for these allergens including denomination of the
causative products; this would greatly enhance both
the reliability and the practical value of published
reports (this statement is valid for all other aller-
gens). Most cases of allergy to quaternium-15 seem
to be related to cosmetic products (49) and this will
probably be the case for the other releasers as well.
Frequency of use
From the FDA data in Table 13, it appears that
approximately 20% of cosmetics and personal care
products in the USA contain a formaldehyde-
releaser (1/6 for stay-on cosmetics, 1/4 for rinse-
off products). No such data are available for
Europe; several older, sometimes selective studies
from Scandinavia (9, 52–55) suggest that the pic-
ture in Europe may be similar. In the USA, the
use of quaternium-15 is decreasing (1996: 3.7%;
2008: 1.4%) and this also holds true for imidazo-
lidinyl urea (1996: 13%; 2008: 7%), though it is
still the most widely used of the formaldehyde-
releasers. DMDM hydantoin usage is stable and
is incorporated far more often in rinse-off prod-
ucts (12.6%) than in stay-on cosmetics (3.0%).
There is a –slight –increase in the usage of
diazolidinyl urea: 3.6% in 1996, 4.5% in 2008.
The other releasers (benzylhemiformal, 5-bromo-5-
nitro-1,3-dioxane, 2-bromo-2-nitropropane-1,3-diol,
formaldehyde, sodium hydroxymethylglycinate) are
used rarely or not at all (benzylhemiformal).
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